Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Paclitaxel |
| Synonyms | |
| Therapy Description |
Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 12 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT01407562 | Phase I | Carboplatin Paclitaxel Pazopanib | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | Completed |
| NCT02651610 | Phase II | Bavituximab Paclitaxel | Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer | Withdrawn |
| NCT02514551 | Phase II | Paclitaxel Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | Completed |
| NCT01501487 | FDA approved | Cyclophosphamide + Docetaxel + Doxorubicin Cyclophosphamide + Epirubicin + Fluorouracil Paclitaxel Pegfilgrastim Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Carboplatin + Docetaxel + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab | MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I | Completed |
| NCT03398655 | Phase III | Paclitaxel Paclitaxel + VB-111 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL) | Recruiting |
| NCT00993655 | Phase III | Cisplatin Paclitaxel Carboplatin | Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed |
| NCT01248949 | Phase I | Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | Completed |
| NCT02302807 | Phase III | Paclitaxel Vinorelbine Atezolizumab Docetaxel | A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | Completed |
| NCT02194829 | Phase Ib/II | Paclitaxel Gemcitabine Adavosertib | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting |
| NCT02038647 | Phase II | Paclitaxel Alisertib | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | Completed |
| NCT01641939 | Phase III | Docetaxel Paclitaxel Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer | Terminated |
| NCT02581943 | Phase II | Paclitaxel Pembrolizumab Carboplatin | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | Active, not recruiting |
| NCT02620865 | Phase Ib/II | Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin | Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Active, not recruiting |
| NCT03141359 | Phase II | Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | Recruiting |
| NCT01572727 | Phase II | Buparlisib + Paclitaxel Paclitaxel | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | Completed |
| NCT01493505 | Phase III | Carboplatin Paclitaxel Trebananib | TRINOVA-3 | Terminated |
| NCT02178956 | Phase III | Napabucasin Paclitaxel | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer | Completed |
| NCT02367794 | Phase III | Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab | A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting |
| NCT02073487 | Phase II | Paclitaxel Ado-trastuzumab emtansine + Lapatinib Lapatinib + Trastuzumab Nab-paclitaxel | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel | Completed |
| NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting |
| NCT01897441 | Phase I | Paclitaxel Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin | Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer | Active, not recruiting |
| NCT02229149 | Phase II | Paclitaxel Docetaxel Pertuzumab + Trastuzumab Nab-paclitaxel Vinorelbine Trastuzumab Capecitabine | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | Active, not recruiting |
| NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed |
| NCT02929576 | Phase III | Paclitaxel Enzalutamide + Paclitaxel Enzalutamide | Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) | Withdrawn |
| NCT02341456 | Phase I | Adavosertib Carboplatin Paclitaxel | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | Completed |
| NCT01792050 | Phase II | Docetaxel Indoximod Paclitaxel | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | Completed |
| NCT02826161 | Phase III | Napabucasin + Paclitaxel Paclitaxel | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) | Terminated |
| NCT02390427 | Phase I | Trastuzumab Paclitaxel Pertuzumab Taselisib | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | Active, not recruiting |
| NCT02502266 | Phase II | Topotecan Paclitaxel Doxorubicin Olaparib Cediranib | Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting |
| NCT02264990 | Phase III | Pemetrexed Carboplatin Paclitaxel Veliparib Cisplatin | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | Completed |
| NCT03430843 | Phase III | Docetaxel Paclitaxel Tislelizumab Irinotecan | A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma | Active, not recruiting |
| NCT01656538 | Phase II | Pelareorep Paclitaxel | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | Completed |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Recruiting |
| NCT01892046 | Phase I | Carboplatin SNX-5422 Paclitaxel | Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Completed |
| NCT01572038 | Phase III | Pertuzumab + Trastuzumab Nab-paclitaxel Docetaxel Paclitaxel | A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) | Completed |
| NCT01281150 | Phase I | Veliparib Paclitaxel Carboplatin | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Completed |
| NCT02142738 | Phase III | Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Active, not recruiting |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed |
| NCT02625623 | Phase III | Avelumab Paclitaxel Irinotecan | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | Completed |
| NCT02412722 | Phase I | Sapanisertib Paclitaxel | Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | Completed |
| NCT02403895 | Phase II | Vistusertib Paclitaxel | AZD2014 and Weekly Paclitaxel in Squamous NSCLC | Terminated |
| NCT02819518 | Phase III | Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | Active, not recruiting |
| NCT04209855 | Phase III | Paclitaxel Pegylated liposomal-doxorubicin Mirvetuximab Soravtansine Topotecan | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) | Recruiting |
| NCT02437812 | Phase II | Paclitaxel Carboplatin Metformin | Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma | Recruiting |
| NCT01962948 | Phase II | Paclitaxel Ganetespib | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated |
| NCT01249443 | Phase I | Carboplatin Vorinostat Paclitaxel | Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | Terminated |
| NCT04177108 | Phase III | Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Recruiting |
| NCT01357161 | Phase II | Carboplatin Adavosertib Paclitaxel | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | Completed |
| NCT03734029 | Phase III | Fam-trastuzumab deruxtecan-nxki Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin | DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Recruiting |
| NCT01952249 | Phase Ib/II | Demcizumab Paclitaxel | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | Terminated |
| NCT02470585 | Phase III | Carboplatin Paclitaxel Veliparib | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting |
| NCT02855944 | Phase III | Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Recruiting |
| NCT03631199 | Phase III | Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) | Active, not recruiting |
| NCT02474173 | Phase I | Paclitaxel Onalespib | HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Active, not recruiting |
| NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed |
| NCT02322281 | Phase III | Pemetrexed Gemcitabine Paclitaxel Docetaxel Rociletinib | TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | Terminated |
| NCT02122770 | Phase I | Paclitaxel Docetaxel Itraconazole Carboplatin MLN4924 Fluconazole | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors | Completed |
| NCT03125902 | Phase III | Paclitaxel Atezolizumab + Paclitaxel | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) | Recruiting |
| NCT02389751 | Phase I | Carboplatin Paclitaxel Ganetespib | A Study of Ganetespib in Combination With Chemoradiation | Completed |
| NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Recruiting |
| NCT01982448 | Phase II | Paclitaxel Cisplatin | Cisplatin vs Paclitaxel for Triple Neg | Active, not recruiting |
| NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab BBI503 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Active, not recruiting |
| NCT02581982 | Phase II | Pembrolizumab Paclitaxel | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | Recruiting |
| NCT02230319 | Phase II | Paclitaxel | Prevention of Paclitaxel Neuropathy With Cryotherapy | Unknown status |
| NCT01042522 | Phase II | Carboplatin Cisplatin Paclitaxel Etoposide Bleomycin | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | Recruiting |
| NCT04109066 | Phase III | Paclitaxel Anthracycline + Cyclophosphamide + Nivolumab Nivolumab + Paclitaxel | Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) | Recruiting |
| NCT02117024 | Phase II | Cyclophosphamide + HS-110 Pemetrexed Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Terminated |
| NCT00828009 | Phase II | Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Active, not recruiting |
| NCT03337724 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) | Recruiting |
| NCT02041533 | Phase III | Nivolumab Paclitaxel Cisplatin Pemetrexed Carboplatin Gemcitabine | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Active, not recruiting |
| NCT02312804 | Phase I | Paclitaxel Carboplatin Infigratinib | Ph Ib/BGJ398/Cervix and Other Solid Tumors | Withdrawn |
| NCT02419495 | Phase I | Cyclophosphamide Pemetrexed Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin | Selinexor in Combination With Standard Chemotherapy | Recruiting |
| NCT03181100 | Phase II | Nab-paclitaxel Paclitaxel Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas | Recruiting |
| NCT02297230 | Phase Ib/II | Capecitabine Paclitaxel Paclitaxel + Trastuzumab | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | Terminated |
| NCT02312245 | Phase II | Topotecan Doxorubicin Paclitaxel Gemcitabine | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting |
| NCT02551055 | Phase I | Docetaxel Paclitaxel Alisertib TAK-659 MLN1117 | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma | Terminated |
| NCT02725268 | Phase II | Paclitaxel Sapanisertib MLN1117 + Sapanisertib | Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer | Active, not recruiting |
| NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting |
| NCT01187199 | Phase I | Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | Active, not recruiting |
| NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Recruiting |
| NCT02187991 | Phase II | Paclitaxel Alisertib + Paclitaxel | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | Active, not recruiting |
| NCT01320592 | Phase I | Palbociclib Paclitaxel | PD0332991/Paclitaxel in Advanced Breast Cancer | Completed |
| NCT01236547 | Phase II | Paclitaxel Pazopanib | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | Active, not recruiting |
| NCT02440425 | Phase II | Paclitaxel Pembrolizumab | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Active, not recruiting |
| NCT03997123 | Phase III | Paclitaxel Capivasertib + Paclitaxel | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290) | Recruiting |
| NCT01215136 | Phase II | Everolimus Paclitaxel | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | Terminated |
| NCT01820754 | Phase II | Cisplatin Ipilimumab Carboplatin Paclitaxel | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | Completed |
| NCT02576574 | Phase III | Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Carboplatin | Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) | Active, not recruiting |
| NCT02301988 | Phase II | Paclitaxel Ipatasertib | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer | Completed |
| NCT03770299 | Phase II | Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Vinorelbine | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) | Withdrawn |
| NCT02134067 | Phase I | TAS-119 Paclitaxel | Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | Terminated |
| NCT01015222 | Phase I | Methylnaltrexone Dasatinib Paclitaxel Bevacizumab | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | Active, not recruiting |
| NCT03517449 | Phase III | Lenvatinib + Pembrolizumab Paclitaxel Doxorubicin | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | Active, not recruiting |
| NCT02574078 | Phase Ib/II | Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Bevacizumab Carboplatin + Pemetrexed Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Gemcitabine | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) | Active, not recruiting |
| NCT02322814 | Phase II | Paclitaxel Cobimetinib | A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer | Active, not recruiting |
| NCT02162719 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer | Completed |
| NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Active, not recruiting |
| NCT03639246 | Phase Ib/II | AVB-S6-500 + Paclitaxel AVB-S6-500 + Pegylated liposomal-doxorubicin Paclitaxel Pegylated liposomal-doxorubicin | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Recruiting |
| NCT01779050 | Phase II | Trastuzumab Docetaxel Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Epirubicin + Fluorouracil Carboplatin + Docetaxel Cyclophosphamide + Docetaxel | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | Active, not recruiting |
| NCT00989651 | Phase I | Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin | Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Active, not recruiting |
| NCT01281176 | Paclitaxel Vorinostat Carboplatin | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | Active, not recruiting | |
| NCT01796197 | Phase II | Cyclophosphamide + Doxorubicin Pertuzumab + Trastuzumab Paclitaxel | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | Active, not recruiting |
| NCT02366949 | Phase I | BAY1217389 + Paclitaxel Paclitaxel | Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | Completed |
| NCT01362374 | Phase I | Enzalutamide Paclitaxel Docetaxel Ipatasertib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors | Active, not recruiting |
CKB BOOST